Author: BusinessWire

March 15, 2021 Off

Gamida Cell Presents Efficacy and Safety Results of Phase 3 Study of Omidubicel in Patients with Hematologic Malignancies at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)

By BusinessWire

-Abstract will be shared at Presidential Symposium and featured in this year’s “Live with Best Abstracts” session-
BOSTON–(BUSINESS WIRE)–Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and seri…